For your skin
A "natural skin lightener" with actual clinical-trial backing for melasma. A placebo-controlled study showed real MASI improvement. Sits well alongside vitamin C, alpha-arbutin, or niacinamide in a brightening stack.
Want the science? Keep reading ↓Mechanism of action
Mulberroside-, oxyresveratrol-, and kuwanon-rich Moraceae extract that competitively inhibits tyrosinase and downregulates melanogenic gene expression in melanocytes; clinically reduced MASI scores in a placebo-controlled melasma trial.
Why we tier this moderate
4 cited papers across 1 country. The mechanism is well-described and there's at least one controlled trial in the literature, but we tier this Moderate rather than Strong to stay honest about how many specific papers we cite directly.
Cited research
Prasawang N, Sutjarit N, Sitthipunya A, et al. Inhibition of Tyrosinase and Melanogenesis by a White Mulberry Fruit Extract. International Journal of Molecular Sciences. 2025 Aug 6;26(15):7589. — Demonstrated dose-dependent inhibition of tyrosinase activity and melanogenesis by white mulberry crude extract in B16F10 cells and zebrafish embryos without cytotoxicity.
Goelzer Neto CF et al., Natural sources of melanogenic inhibitors: A systematic review, International Journal of Cosmetic Science 2022;44(2):143-153 — SR identifying Morus alba (mulberry) as a notable melanogenesis inhibitor
Zhang L et al., Moraceae Plants with Tyrosinase Inhibitory Activity: A Review, Mini Reviews in Medicinal Chemistry 2017;17(13):1148-1157 — Morus alba and related Moraceae compounds demonstrate enzymatic tyrosinase inhibition and clinical whitening effects competitive with available depigmenting agents
Alvin G et al., A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma, Journal of Drugs in Dermatology 2011;10(9):1025-1031 — RCT: topical 75% mulberry extract significantly reduced MASI and Mexameter readings and improved QoL vs placebo with minimal adverse events
Sources: 10 clinical journals and regulatory databases across the US, EU, Korea, Japan, and China. Every entry points to a specific document. See methodology for the full list and what each outcome label means.